Hyperbaric oxygen for carbon monoxide poisoning
Authors:
- Mb StanbrookMSMb Stanbrook
- MA McGuiganMMMA McGuigan
- 24 April 2000
- reference entry
- Published by Wiley
- No. 2,p. CD002041
Abstract
Poisoning with carbon monoxide (CO) remains an important cause of accidental and intentional injury worldwide. Several unblinded nonrandomized trials have suggested that the use of hyperbaric oxygen (HBO) prevents the development of neurological sequelae. This has led to the widespread use of HBO in the management of patients with carbon monoxide poisoning. To assess the effectiveness of hyperbaric oxygen (HBO) compared to normobaric oxygen (NBO) for the prevention of neurologic symptoms in patients with acute carbon monoxide poisoning. We searched MEDLINE (1966-present), EMBASE (1980-present), and the Controlled Trials Register of the Cochrane Collaboration, supplemented by a manual review of bibliographies of identified articles and discussion with recognized content experts. All randomized controlled trials involving non pregnant adults acutely poisoned with carbon monoxide, regardless of severity, with adequate or unclear allocation concealment were examined. Trials with a score of 3 out of 5 or higher on the validity instrument of Jadad were included in the primary analysis. Two reviewers independently extracted from each trial information on the number of randomized patients, types of participants, the dose and duration of the intervention, and the prevalence of neurologic symptoms at follow-up. A pooled odds ratio (OR) for the presence of neurologic symptoms at one month follow-up was calculated using a random effects model. Six randomized controlled trials were identified. The trials were of varying quality. Three trials employing different doses of NBO and HBO were included in the primary analysis. The severity of CO poisoning was inconsistent between trials. At one month follow-up after treatment, symptoms possibly related to carbon monoxide poisoning were present in 81 of 237 patients (34.2%) treated with HBO, compared with 81 of 218 patients (37.2%) treated with NBO (O.R. for benefit with HBO 0.82; 95% CI 0.41-1.66). There is no evidence that unselected use of HBO in the treatment of acute CO poisoning reduces the frequency of neurological symptoms at one month. However, evidence from the available randomized controlled trials is insufficient to provide clear guidelines for practice. Further research is needed to better define the role of HBO, if any, in the treatment of carbon monoxide poisoning. This research question is ideally suited to a multicentre, randomized, double-blind controlled trial.Keywords
This publication has 8 references indexed in Scilit:
- CARBON MONOXIDE POISONINGCritical Care Clinics, 1999
- Hyperbaric or normobaric oxygen for acute carbon monoxide poisoning: a randomised controlled clinical trialMedical Journal of Australia, 1999
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Delayed Neuropsychologic Sequelae After Carbon Monoxide Poisoning: Prevention by Treatment With Hyperbaric OxygenAnnals of Emergency Medicine, 1995
- Empirical Evidence of BiasJAMA, 1995
- Carbon Monoxide Controversies: Neuropsychologic Testing, Mechanism of Toxicity, and Hyperbaric OxygenAnnals of Emergency Medicine, 1994
- TRIAL OF NORMOBARIC AND HYPERBARIC OXYGEN FOR ACUTE CARBON MONOXIDE INTOXICATIONThe Lancet, 1989
- Carbon Monoxide Intoxication: Clinical Features, Neuropathology and Mechanisms of InjuryJournal of Toxicology: Clinical Toxicology, 1985